Metformin overcomes IL-6-induced EGFR-TKI resistance in TKI-sensitive lung cancer cells through the inhibition of STAT3 and AKT phosphorylation and the enhancement of AMPK activation14. This evidence concerns the gene EGFR and lung carcinoma.